These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 7505345)
1. [Changes in coagulation and fibrinolytic factors observed during heparin-urokinase-pulse combined therapy for nephritis resistant to conventional treatment in children]. Koitabashi Y; Ikoma M; Shibawaka T; Yamaguchi Y; Mio H; Doi K; Meguro T; Yamada K Nihon Jinzo Gakkai Shi; 1993 Oct; 35(10):1155-61. PubMed ID: 7505345 [TBL] [Abstract][Full Text] [Related]
2. Enhanced fibrinolytic activity during the course of hemodialysis. Nakamura Y; Tomura S; Tachibana K; Chida Y; Marumo F Clin Nephrol; 1992 Aug; 38(2):90-6. PubMed ID: 1387598 [TBL] [Abstract][Full Text] [Related]
3. [Combined use of heparin and urokinase in the patients with nephritis resistant to the conventional treatment and the significance of alpha 2-plasmin inhibitor in the therapy (author's transl)]. Koitabashi Y; Maruyama T; Ikoma M; Miyaji Y; Yamada K; Shimizu K Rinsho Ketsueki; 1982 Mar; 23(3):309-18. PubMed ID: 7050462 [No Abstract] [Full Text] [Related]
4. [An experimental study of local fibrinolysis using tissue plasminogen activator and urokinase in a canine common carotid artery thrombus model]. Kawakami K; Takahashi A; Yoshimoto T No To Shinkei; 1990 Feb; 42(2):193-201. PubMed ID: 2113401 [TBL] [Abstract][Full Text] [Related]
5. [Serial changes in hemostatic molecular markers after urokinase therapy of acute myocardial infarction]. Goto S; Kawai Y; Watanabe K; Hori S; Abe S; Handa S; Ikeda Y Kokyu To Junkan; 1992 Jan; 40(1):89-95. PubMed ID: 1532665 [TBL] [Abstract][Full Text] [Related]
6. [Serial changes in hemostatic and fibrinolytic states induced by coronary thrombolytic therapy]. Goto S; Handa S; Abe S; Takahashi E; Kawai Y; Watanabe K; Yoshikawa T; Hori S; Ikeda Y J Cardiol; 1993; 23(4):335-41. PubMed ID: 8064582 [TBL] [Abstract][Full Text] [Related]
7. [Activation of fibrynolysis in children with chronic B or C hepatitis]. Michalska K; Szaflarska-Popławska A; Dymek G; Kotschy M Pol Merkur Lekarski; 2004 Oct; 17(100):316-20. PubMed ID: 15690691 [TBL] [Abstract][Full Text] [Related]
8. Effects of direct percutaneous transluminal coronary angioplasty treatment of acute myocardial infarction on plasma levels of haemostatic and fibrinolytic factors. Saito M; Nakabayashi T; Iuchi K; Ishikawa T; Kaseno K; Yoshida T; Asakura H; Matsuda T Blood Coagul Fibrinolysis; 1993 Oct; 4(5):801-4. PubMed ID: 7507363 [TBL] [Abstract][Full Text] [Related]
9. Plasma levels and urinary excretion of fibrinolytic and protease inhibitory proteins in nephrotic syndrome. Vaziri ND; Gonzales EC; Shayestehfar B; Barton CH J Lab Clin Med; 1994 Jul; 124(1):118-24. PubMed ID: 7518491 [TBL] [Abstract][Full Text] [Related]
10. Systemic fibrinolytic activity and inhibitor levels during treatment of deep vein thrombosis with urokinase and streptokinase. Theiss W; Asbeck F; Kriessmann A; Trübestein G; Knoch K; de Swart CA; Marbert GA; van de Loo JC Thromb Haemost; 1983 Oct; 50(3):664-8. PubMed ID: 6196852 [TBL] [Abstract][Full Text] [Related]
11. Levels of fibrinolytic activators and inhibitors in plasma after severe trauma. Sørensen JV Blood Coagul Fibrinolysis; 1994 Feb; 5(1):43-9. PubMed ID: 7514044 [TBL] [Abstract][Full Text] [Related]
12. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways. Munkvad S Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763 [TBL] [Abstract][Full Text] [Related]
13. The fibrinolytic system in neoplasia. Bell WR Semin Thromb Hemost; 1996; 22(6):459-78. PubMed ID: 9122711 [TBL] [Abstract][Full Text] [Related]
14. [The changes of alpha 2-plasmin inhibitor, and notably urokinase activities in blood measured by synthetic chromogenic substrates S-2444 after urokinase administration]. Itoh Y; Tsuji K; Tanaka N; Yamada M; Nakanishi M; Ishihara M; Kobayashi M Nihon Sanka Fujinka Gakkai Zasshi; 1983 Jan; 35(1):68-76. PubMed ID: 6338134 [TBL] [Abstract][Full Text] [Related]
15. [Measurements of plasmin-alpha 2 plasmin inhibitor complex and FDP.D dimer levels in the fibrinolytic therapy of acute pulmonary thromboembolism]. Yamasawa F; Hasegawa N; Asano K; Sayama K; Fujita H; Urano T; Aoki T; Ishizaka A; Kanazawa M; Kawashiro T Kokyu To Junkan; 1992 Jul; 40(7):685-90. PubMed ID: 1387724 [TBL] [Abstract][Full Text] [Related]
16. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro. Matsuo O; Rijken DC; Collen D Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339 [TBL] [Abstract][Full Text] [Related]
17. Fibrinolysis system in patients with bronchial asthma. Banach-Wawrzeńczyk E; Dziedziczko A; Rość D Med Sci Monit; 2000; 6(1):103-7. PubMed ID: 11208294 [TBL] [Abstract][Full Text] [Related]
18. Novel distribution pattern of fibrinolytic components in rabbit tissues extract: a preliminary study. Lu XG; Wu XG; Xu XH; Gong XB; Zhou X; Xu GB; Zhu L; Zhao XY J Zhejiang Univ Sci B; 2007 Aug; 8(8):570-4. PubMed ID: 17657859 [TBL] [Abstract][Full Text] [Related]
19. Modifications in coagulation parameters induced by treatment associating urokinase (2000 u CTA/kg/h) with heparin. Juhan I; Calas MF; Buonocore M; Mathieu P; Isnard G; Cazenave B; Serradimigni A Thromb Haemost; 1979 Oct; 42(3):945-54. PubMed ID: 315625 [No Abstract] [Full Text] [Related]
20. [Levels of tissue-type plasminogen activator and plasminogen activator inhibitor 1 in disseminated intravascular coagulation syndrome]. Fukao H; Yamamoto K; Matsuo O Rinsho Byori; 1991 Jul; 39(7):720-6. PubMed ID: 1920864 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]